Alemtuzumab: non-autoimmune complications
Evidence-based neurology checklist on alemtuzumab: non-autoimmune complications: Cytokine release infusion-related syndrome Flushing Headache Pruritus Rash Fever Cardiovascular infusion-related side effects Infections Malignancies Gastrointestinal Inflammatory Pulmonary Miscellaneous side effects
Cytokine release infusion-related syndrome
- Flushing
- Headache
- Pruritus
- Rash
- Fever
Cardiovascular infusion-related side effects
Infections
Malignancies
Gastrointestinal
Inflammatory
Pulmonary
Miscellaneous side effects
References
- Coles AJ, Cohen JA, Fox EJ, et al; CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings. Neurology 2017; 89:1117-1126.
- Ferraro D, Camera V, Vitetta F, et al. Acute coronary syndrome associated with alemtuzumab infusion in multiple sclerosis. Neurology 2018; 90:852-854.
- Havrdova E, Arnold DL, Cohen JA, et al; CARE-MS I and CAMMS03409 Investigators. Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy. Neurology 2017; 89:1107-1116.
- Pfeuffer S, Beuker C, Ruck T, et al. Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS. Neurology 2016; 87:2380-2381.
- Croteau D, Flowers C, Kulick CG, Brinker A, Kortepeter CM. Acute acalculous cholecystitis: a new safety risk for patients with MS treated with alemtuzumab. Neurology 2018; 90:e1548-e1552.
- And 19 more. Subscribe to see the full list
